The aforementioned findings motivated us to investigate the impact of FASN on immunotherapy, and we found that FASN expression was significantly negatively correlated with key targets of immune checkpoint blockade therapy, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), in up to 15 cancer types [24], especially in LGG (Figure 6A). Here, FASN is linked to cancer.